Preliminary results of main portal vein tumor thrombus treated by endovascular brachytherapy combined with sorafenib

10^th Global Annual Oncologists Meeting

July 11-13, 2016 Cologne, Germany

Zhi-Ping Yan, Jian-Jun Luo, Qing-Xin Liu, Wen Zhang and Zi-Han Zhang

Zhongshan Hospital, China

Posters & Accepted Abstracts: J Cancer Sci Ther

Abstract :

Propose: To evaluate the safety and efficacy of endovascular brachytherapy (EVBT) with Iodine-125 (125I) seeds strand implantation combined with stent placement and transarterial chemoembolization (TACE) followed by Sorafenib to treat hepatocellular carcinoma (HCC) with main portal vein tumor thrombus (MPVTT). Methods: From January 2009 to December 2014, data of 30 consecutive HCC patients with MPVTT treated by TACE and Sorafenib were analyzed retrospectively. 125I seeds strand and stent were implanted in the main portal vein of 18 patients (Group A). The remaining 12 patients, who did not receive EVBT, served as control (Group B). The overall survival, progression-free survival, and treatment-related adverse events were compared between two groups. Results: All locoregional and Sorafenib therapy were implemented successfully without serious treatment-related adverse events. During a mean of 12.0�±12.1 months (range 2.2â��62.5 months) follow-up, the median survival time was 18.4�±8.1 months (95% CI, 2.6â��34.2 months) in Group A, compared to 7.0�±1.3 months (95% CI, 4.5â��9.5 months) in Group B (p<0.001). Median progression-free survival time in Group A and B was 8.5�±5.3 months (95% CI, 0.0â��18.9 months) and 3.4�±1.0 mouths (95% CI, 1.5â��5.3 months) respectively (p<0.001). Conclusion: Our preliminary results suggested that endovascular brachytherapy combined with Sorafenib might be a safe and effective palliative treatment option for main portal vein tumor thrombus.

Biography :

Email: yan.zhiping@hotmail.com